Laboratory-Clinic InterfaceAll about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer
Introduction
The application of molecular targeted therapeutics into daily clinical practice has surfaced the need for biomarkers for patient stratification and clinical decision-making. Predictive biomarkers, if appropriately developed, validated and employed, can identify patients who are most likely to benefit from treatment or spare patients that have tumors with ‘de novo’ resistance to a given agent from ineffective or toxic treatments. In this way they can improve clinical outcomes and assist in reducing healthcare costs.1, 2
Although research for biomarker discovery and validation has been actively pursued for many years,3 to date there are only a handful incorporated into daily oncology practice. One of the most notable is HER2 over-expression in breast cancer as assessed by immunohistochemistry or gene amplification as assessed by in situ hybridization (ISH), wherein the biomarker is both predictive of response to HER2-targeted agents and prognostic of outcome in patients not treated with anti-HER2 therapies.2, 4 More recent developments regarding small molecule tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), gefitinib (IRESSA™) and erlotinib (TARCEVA™), have demonstrated the potential of using a biomarker (EGFR mutations) to guide treatment selection for non-small-cell lung cancer (NSCLC)5, 6, 7, 8, 9 and have underlined the importance of the EGFR pathway in tumor biology and drug development.
Over the last decade, with the explosion of information concerning signaling pathways that have a bearing on carcinogenesis, it has become evident that there are a number of central ‘hubs’ that reflect keys to unlocking our ability to predict response when any one particular pathway is targeted in cancer.10, 11 In the complexity of signaling pathways that exist in the cellular milieu, RAS represents such a hub.12 Today KRAS is receiving unprecedented interest following the identification of a link between KRAS somatic mutations and non-responsiveness to anti-EGFR based treatment strategies in metastatic colorectal cancer.13 Here we provide an overview of KRAS function at a molecular level, discuss practical aspects of KRAS mutational testing and offer some recommendations for its application in the clinical management of metastatic colorectal cancer patients.
Section snippets
G proteins
More than 30 years ago, the RAS gene was identified by Edward Scolnick and colleagues initially as a viral gene with oncogenic properties (Rat Sarcoma Virus) and was later characterized as a transforming gene related to carcinogenesis.14, 15, 16 It has taken some time to understand the complexities of its downstream signaling network due to the extensive cross-talk between divergent pathways. RAS belongs to the small GTP-binding (guanine triphosphate) protein super-family (G proteins). These are
Prognostic significance
Mutations of RAS family members have been identified in approximately 30% of all human malignancies. Some tumors such as pancreatic, colorectal and unknown primary cancers have high mutation rates, ranging from 40% to 90%, indicating the significance of this molecule as a target for cancer therapy.39, 40, 41 The most commonly identified mutations indentified in the KRAS gene in human solid tumors lead to aminoacid substitutions in codons 12, 13 and 61 of the KRAS protein, although mutations
Methodological aspects
Given the value of KRAS mutations for predicting benefit from anti-EGFR antibodies, and the labeling changes enforced by the EMA and the FDA, the implementation of KRAS screening in routine clinical practice is expanding. Furthermore, the constitutive signaling of RAS (in the presence of mutations) extends to include already recognized signaling pathway members that lead to similar constitutive signaling of the RAF-MEK-ERK and PI3K-AKT pathways promoting cell growth and survival in the absence
Future role of KRAS
As our understanding of resistance to anti-EGFR treatment continuous to grow, additional molecular biomarkers will soon be added to the current landscape of predictive biomarkers.
Here we predict that there may be two main approaches to treatment selection for “personalized” management: (1) through the multiplexing of specific somatic mutations in the candidate genes BRAF,62, 63 PIK3CA, PTEN63 and (2) through high-dimensional gene expression or proteomic signature approaches, possibly inclusive
Conclusions
RAS, a member of G-protein coding super-family of genes, has received much clinical attention recently, following the discovery of the therapeutic implications of its mutational status for targeted therapies directed against c-erbB proteins. There is a continued concerted effort in many countries to undertake KRAS mutational analysis. Each laboratory is addressing its particular needs, many of which are being tackled by the formation of investigator networks and international collaborations.103
Ethics and funding source
This was a literature based study and as such no ethics approval was required.
There was no funding source associated with the study design, collection, and analysis, interpretation of the data or writing of the report.
Conflict of interest
Consultant or Advisory role: Dr. S. Murray, Merck KGaA, Darmstadt, Germany. Merck distribute the MoAb Cetuximab (Erbitux®). Dr. S. Murray and Dr. P. Kosmidis, AstraZeneca, Maccelsfield, United Kingdom. AstraZeneca are proprietors of gefitinib (Iressa®). Dr. S. Murray, Amgen Thousand Oaks, CA, USA. Amgen distribute the MoAb Panitumumab (Vectibix®). No other author has a conflict of interest.
Author contributions
I.J.D., H.L., E.B., P.K., D.B., and S.M. participated in the conception and design of the study; H.L., I.J.D., G.M., S.P., and S.M. participated in the extraction, interpretation, supply, and synthesis of data. H.L., I.J.D., E.B., G.M., C.P., and S.M. participated in the writing of the report, and all authors approved the final version. No external financial support was provided for this project, and H.L., C.P., P.K., D.B., and S.M. provided administrative support. All authors approved the
Research methodology
The information for this review was obtained by searching the MEDLINE database for articles published until 1st May 2010. Electronic early-release publications were also included. We searched journals known to publish information relevant to our topic, and cross-referenced the reference lists of recovered articles. We did not impose language restrictions. Search terms included: cancer, colon, rectal, colorectal neoplasms, non-small-cell lung cancer, mutation and KRAS. Cell line and other in
References (117)
- et al.
Methodological issues in the economic analysis of cancer treatments
Eur J Cancer.
(2006) - et al.
Bringing molecular prognosis and prediction to the clinic
Clin Breast Cancer
(2005) - et al.
EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences
Crit Rev Oncol Hematol
(2007) Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?
Ann Oncol
(2008)- et al.
Signaling interplay in Ras superfamily function
Curr Biol
(2005) - et al.
All ras proteins are polyisoprenylated but only some are palmitoylated
Cell
(1989) - et al.
Farnesyltransferase inhibitors
Semin Oncol
(2004) - et al.
Desensitization of Ras activation by a feedback disassociation of the SOS–Grb2 complex
J Biol Chem
(1995) - et al.
Many faces of Ras activation
Biochim Biophys Acta
(2008) - et al.
The interaction of Ras with GTPase-activating proteins
FEBS Lett
(1997)
Consequences of weak interaction of rho GDI with the GTP-bound forms of rho p21 and rac p21
J Biol Chem
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice
Cell
Almost all articles on cancer prognostic markers report statistically significant results
Eur J Cancer
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Lancet Oncol
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
Ann Oncol
Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications
J Mol Diagn
A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting
J Mol Diagn
The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR
Biochem Biophys Res Commun
KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology
J Mol Diagn
Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods
J Mol Diagn
Approach to analysis of single nucleotide polymorphisms by automated constant denaturant capillary electrophoresis
Mutat Res
Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group
Lancet
Clinical trials for predictive medicine: new challenges and paradigms
Clin Trials
Molecular epidemiology of cancer
CA Cancer J Clin
Small molecules with EGFR-TK inhibitor activity
Curr Drug Targets
Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?
J Clin Oncol
Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer
Clin Cancer Res
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
Nat Rev Clin Oncol
An integrative approach to characterize disease-specific pathways and their coordination: a case study in cancer
BMC Genomics
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
Cancer Res
Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus
Nature
Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses
Proc Natl Acad Sci USA
DNA synthesis by RNA-containing tumor viruses
Proc Natl Acad Sci USA
The G-protein family and their interaction with receptors
Endocr Rev
Hyperactive Ras in developmental disorders and cancer
Nat Rev Cancer
Common modifications of trimeric G proteins and ras protein: involvement of polyisoprenylation
Science
Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation
Proc Natl Acad Sci USA
The p21 ras C-terminus is required for transformation and membrane association
Nature
Posttranslational modification of Ha-ras p21 by farnesyl versus geranylgeranyl isoprenoids is determined by the COOH-terminal amino acid
Proc Natl Acad Sci USA
Novel determinants of H-Ras plasma membrane localization and transformation
Oncogene
N-terminally myristoylated Ras proteins require palmitoylation or a polybasic domain for plasma membrane localization
Mol Cell Biol
Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem
Curr Med Chem
The structural basis for the transition from Ras-GTP to Ras-GDP
Proc Natl Acad Sci USA
GTPase activating proteins: structural and functional insights 18 years after discovery
Cell Mol Life Sci
Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding
J Cell Biol
Mind the GAP, Rho, Rab and GDI
Nat Genet
Disruption of the Rb–Raf-1 interaction inhibits tumor growth and angiogenesis
Mol Cell Biol
Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation
Mol Cell Biol
K-ras and p16 aberrations confer poor prognosis in human colorectal cancer
J Clin Oncol
Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin
Anticancer Res
Cited by (40)
Combining competitive sequestration with nonlinear hybridization chain reaction amplification: an ultra-specific and highly sensitive sensing strategy for single-nucleotide variants
2020, Analytica Chimica ActaCitation Excerpt :Then we further applied the developed strategy to the analysis of human genomic DNA extracted from cell samples. According to previous reports [51,52], we extracted the KRAS G12D (c.35G > A) sequence from Panc-1 cancer cell lines and the WT sequence from HT-29 cancer cell lines. The extracted genomic KRAS G12D (c.35G > A) target and WT were mixed at 0 : 100, 0.05 : 99.95, 0.1 : 99.9, 0.5 : 99.5, 1 : 99 and 100 : 0 ratios and amplified by PCR.
The right drugs at the right time for the right patient: The MD Anderson precision oncology decision support platform
2015, Drug Discovery TodayCitation Excerpt :Additionally, our scheme considers genotypes that confer resistance to a therapy. For example, KRAS mutations confer resistance to anti-epidermal growth factor receptor (EGFR) therapies in colon cancer [24,25], thus colon cancer patients harboring activating KRAS mutations should not be treated with these therapies outside of clinical trials assessing ways to bypass the effects of KRAS. Thus, it is crucial to consider the therapeutic implications of alterations in the context of one another.
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
2021, Molecular CancerDirect Detection of Low Abundance Genes of Single Point Mutation
2021, Nano Letters